• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy

Kalra, Jaspreet; Mangali, Suresh Babu; Dasari, Deepika; Bhat, Audesh; Goyal, Srashti; Dhar, Indu; Sriram, Dharamrajan; Dhar, Arti
Peer reviewed, Journal article
Accepted version
Thumbnail
View/Open
Accepted version (1.902Mb)
URI
https://hdl.handle.net/1956/22089
Date
2020
Metadata
Show full item record
Collections
  • Department of Clinical Science [1056]
Original version
Kalra J, Mangali SB, Dasari, Bhat A, Goyal, Dhar I, Sriram D, Dhar A. SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. Fundamental & Clinical Pharmacology. 2020;34(2):173-188   https://doi.org/10.1111/fcp.12516
Abstract
Chronic hyperglycaemia is a peculiar feature of diabetes mellitus (DM). Sequential metabolic abnormalities accompanying glucotoxicity are some of its implications. Glucotoxicity most likely corresponds to the vascular intricacy and metabolic alterations, such as increased oxidation of free fatty acids and reduced glucose oxidation. More than half of those with diabetes also develop cardiac abnormalities due to unknown causes, posing a major threat to the currently available marketed preparations which are being used for treating these cardiac complications. Even though impairment in cardiac functioning is the principal cause of death in individuals with type 2 diabetes (T2D), reducing plasma glucose levels has little effect on cardiovascular disease (CVD) risk. In vitro and in vivo studies have demonstrated that inhibitors of sodium glucose transporter (SGLT) represent a putative therapeutic intervention for these pathological conditions. Several clinical trials have reported the efficacy of SGLT inhibitors as a novel and potent antidiabetic agent which along with its antihyperglycaemic activity possesses the potential of effectively treating its associated cardiac abnormalities. Thus, hereby, the present review highlights the role of SGLT inhibitors as a successful drug candidate for correcting the shifts in deregulation of cardiac energy substrate metabolism together with its role in treating diabetes‐related cardiac perturbations.
Description
Under embargo until: 2020-11-07
Publisher
Wiley
Journal
Fundamental & Clinical Pharmacology
Copyright
Copyright 2019 Société Française de Pharmacologie et de Thérapeutique

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit